Celldex Therapeutics logo

Celldex Therapeutics

CLDX | NASDAQ
Chart Builder DCF Calculator
$28.59
-$0.24 (-0.83%)
At close: Nov 16, 2026, 4:00 PM ET
$29.00
+$0.41 (+1.43%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.83%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
22.9
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #969/1021 (Top 95%)

Key Statistics

Market Data

Market Cap $2.25B
1D Range
28.33 29.08
52W Range
22.58 44.87

Valuation (TTM)

PE -6.63
PB 3.46
EV/EBITDA -5.26

Valuation (NTM)

Forward PE N/A
Forward PEG -0.67
Price Target $62.50
Loading financial charts...

Profile

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline ...

Sector Healthcare
Industry Biotechnology
Employees 198
IPO Date May 15, 1986
Fiscal Year January - December

Latest News

Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results

7 days ago · marketbeat.com

Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results

2 months ago · seekingalpha.com

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

2 months ago · benzinga.com

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

2 months ago · zacks.com

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

2 months ago · reuters.com

Celldex's skin disease drug meets goals in two late-stage trials
Celldex to Present at Upcoming Investor Conference

2 months ago · globenewswire.com

Celldex to Present at Upcoming Investor Conference
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

3 months ago · zacks.com

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

4 months ago · zacks.com

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

4 months ago · seekingalpha.com

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

4 months ago · benzinga.com

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.96
Beat +5.88%
REV
$400K
Miss -44.65%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$62.50
Upside
+118.61%
Buy (10)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.